GEn1E Lifesciences

Palo Alto, CA · Founded 2018 · Privately Held (backing)

Developer of artificial intelligence-powered precision therapies designed to address immunology, inflammatory, rare, and oncologic diseases. GEn1E Lifesciences is based in Palo Alto, CA and was founded in 2018. It was valued at $136 million at its early-stage round in Dec 2025, the last priced event on record. It has raised $25.6 million across 2 recorded rounds; the latest was a $5.5 million early-stage round in Oct 2025.

PMV mark · valuation
$135.5M
Oct 2026
Priced at
its early-stage round
Dec 2025
Total raised
$25.6M
Last round
Early Stage VC
Oct 2025

Who backs GEn1E Lifesciences?

38 investors
InvestorType
Y CombinatorOther
Khosla VenturesVenture capital
GaingelsVenture capital
StartX (US)Other
BoxOne VenturesOther
Vision Capital GroupHedge fund
Jeffery BrownAngel
Vision Capital Ventures—
John-Paul Gallo—
10X Capital—
+ 28 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

GEn1E Lifesciences investors

38 investors are on record for GEn1E Lifesciences, including Y Combinator, Khosla Ventures, Gaingels and StartX (US). The early-stage round in Oct 2025 drew 44 investors.

Free account
More of GEn1E Lifesciences with a free account
  • ·The complete investor list: 38 names
  • ·Watch GEn1E Lifesciences: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 38 firms already write checks for companies like GEn1E Lifesciences. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View